Publications by authors named "Jeffrey T Ha"
Background: Hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors are an oral treatment for anemia of chronic kidney disease (CKD). In this systematic review and meta-analysis, we assessed long-term safety of HIF prolyl hydroxylase inhibitors.
Methods: We searched MEDLINE, Embase, and Cochrane databases for randomized trials comparing HIF prolyl hydroxylase inhibitors with an erythropoiesis-stimulating agent (ESA) or placebo with greater than or equal to 48 weeks of follow-up.
Background: With rising costs and burden of chronic kidney disease (CKD), timely referral of patients to a kidney specialist is crucial. Currently, Kidney Health Australia (KHA) uses a 'heat map' based on severity and not future risk of kidney failure, whereas the kidney failure risk equation (KFRE) score predicts future risk of progression.
Aims: Evaluate whether a KFRE score assists with timing of CKD referrals.
Article Synopsis
- The study investigates whether chronic kidney disease (CKD) acts as an independent risk factor for developing atrial fibrillation (AF), employing a systematic review and meta-analysis of cohort studies and trials involving participants with glomerular filtration rate (eGFR) and albuminuria measurements.
- Results from 38 studies show that lower eGFR and the presence of albuminuria significantly increase the risk of incident AF, with a clear trend indicating higher risks at lower eGFR levels and higher albuminuria categories.
- Limitations of the study include the absence of individual patient data, inability to assess the interaction between eGFR and albuminuria, and potential biases due to varying methods used for detecting AF.
Rationale & Objective: The benefit-risk profile of rivaroxaban versus warfarin for atrial fibrillation (AF) in patients with chronic kidney disease is uncertain. We compared rivaroxaban with warfarin across the range of kidney function in adults with AF.
Study Design: Multicenter retrospective cohort.
Background: Effects of oral anticoagulation in chronic kidney disease (CKD) are uncertain.
Purpose: To evaluate the benefits and harms of vitamin K antagonists (VKAs) and non-vitamin K oral anticoagulants (NOACs) in adults with CKD stages 3 to 5, including those with dialysis-dependent end-stage kidney disease (ESKD).
Data Sources: English-language searches of MEDLINE, EMBASE, and Cochrane databases (inception to February 2019); review bibliographies; and ClinicalTrials.
Recent evidence for direct oral anticoagulants in chronic kidney disease.
Curr Opin Nephrol Hypertens
May 2019
Purpose Of Review: The direct oral anticoagulants (DOACs) have emerged as an effective and safe alternative to vitamin K antagonists (VKAs) for stroke and venous thromboembolism (VTE) prevention. However, patients with chronic kidney disease (CKD) experience an increase in the risk of both thromboembolism and bleeding, and the risk-benefit profile of DOACs, particularly in advanced CKD remains a source of ongoing debate. This review summarizes the recent evidence on the effects of DOACs in CKD across a range of clinical indications including newly emerging indications.
View Article and Find Full Text PDF